<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">World J Surg Oncol</journal-id>
      <journal-title>World Journal of Surgical Oncology</journal-title>
      <issn pub-type="epub">1477-7819</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">18430248</article-id>
      <article-id pub-id-type="pmc">2386474</article-id>
      <article-id pub-id-type="publisher-id">1477-7819-6-41</article-id>
      <article-id pub-id-type="doi">10.1186/1477-7819-6-41</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Surgical treatment of a rare primary renal carcinoid tumor with liver metastasis</article-title>
      </title-group>
      <contrib-group>
        <contrib id="A1" corresp="yes" contrib-type="author">
          <name>
            <surname>Gedaly</surname>
            <given-names>Roberto</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>rgeda2@uky.edu</email>
        </contrib>
        <contrib id="A2" contrib-type="author">
          <name>
            <surname>Jeon</surname>
            <given-names>Hoonbae</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>rgeda2@uky.edu</email>
        </contrib>
        <contrib id="A3" contrib-type="author">
          <name>
            <surname>Johnston</surname>
            <given-names>Thomas D</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>tdjohn1@uky.edu</email>
        </contrib>
        <contrib id="A4" contrib-type="author">
          <name>
            <surname>McHugh</surname>
            <given-names>Patrick P</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>patrick.mchugh@uky.edu</email>
        </contrib>
        <contrib id="A5" contrib-type="author">
          <name>
            <surname>Rowland</surname>
            <given-names>Randall G</given-names>
          </name>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>rrowlan@email.uky.edu</email>
        </contrib>
        <contrib id="A6" contrib-type="author">
          <name>
            <surname>Ranjan</surname>
            <given-names>Dinesh</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>dranj1@uky.edu</email>
        </contrib>
      </contrib-group>
      <aff id="I1"><label>1</label>Division of Transplantation and Hepatobiliary Surgery, Department of Surgery, University of Kentucky Medical Center, Lexington, Kentucky, USA</aff>
      <aff id="I2"><label>2</label>Division of Urology, Department of Surgery, University of Kentucky Medical Center, Lexington, Kentucky, USA</aff>
      <pub-date pub-type="collection">
        <year>2008</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>22</day>
        <month>4</month>
        <year>2008</year>
      </pub-date>
      <volume>6</volume>
      <fpage>41</fpage>
      <lpage>41</lpage>
      <ext-link ext-link-type="uri" xlink:href="http://www.wjso.com/content/6/1/41"/>
      <history>
        <date date-type="received">
          <day>31</day>
          <month>1</month>
          <year>2008</year>
        </date>
        <date date-type="accepted">
          <day>22</day>
          <month>4</month>
          <year>2008</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2008 Gedaly et al; licensee BioMed Central Ltd.</copyright-statement>
        <copyright-year>2008</copyright-year>
        <copyright-holder>Gedaly et al; licensee BioMed Central Ltd.</copyright-holder>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0">
          <p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p>
          <!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author>
               Gedaly
               Roberto
               
               rgeda2@uky.edu
            </dc:author><dc:title>
            Surgical treatment of a rare primary renal carcinoid tumor with liver metastasis
         </dc:title><dc:date>2008</dc:date><dcterms:bibliographicCitation>World Journal of Surgical Oncology 6(1): 41-. (2008)</dcterms:bibliographicCitation><dc:identifier type="sici">1477-7819(2008)6:1&#x0003c;41&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1477-7819</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>-->
        </license>
      </permissions>
      <abstract>
        <sec>
          <title>Background</title>
          <p>Carcinoid tumors are characteristically low grade malignant neoplasms with neuroendocrine differentiation that arise in various body sites, most commonly the lung and gastrointestinal tract, but less frequently the kidneys, breasts, ovaries, testes, prostate and other locations. We report a case of a carcinoid of renal origin with synchronous single liver metastases on radiological studies.</p>
        </sec>
        <sec>
          <title>Case presentation</title>
          <p>A 45 year-old patient who presented with abdominal pain was found on CT scan to have lesions in the right ovary, right kidney, and left hepatic lobe. CA-125, CEA, and CA 19-9 were within normal limits, as were preoperative liver function tests and renal function. Biopsy of the liver mass demonstrated metastatic neuroendocrine tumor. At laparotomy, the patient underwent total abdominal hysterectomy with bilateral salpingo-oophorectomy, radical right nephrectomy with lymphadenectomy, and left hepatectomy. Pathology evaluation reported a right ovarian borderline serous tumor, well-differentiated neuroendocrine carcinoma of the kidney (carcinoid) with 2 positive retroperitoneal lymph nodes, and a single liver metastasis. Immunohistochemistry revealed that this lesion was positive for synaptophysin and CD56, but negative for chromogranin as well as CD10, CD7, and CD20, consistent with a well-differentiated neuroendocrine tumor. She is doing well one year after her initial surgery, with no evidence of tumor recurrence.</p>
        </sec>
        <sec>
          <title>Conclusion</title>
          <p>Early surgical intervention, together with careful surveillance and follow-up, can achieve successful long-term outcomes in patients with this rare malignancy.</p>
        </sec>
      </abstract>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Background</title>
      <p>Neuroendocrine carcinomas may originate in a wide variety of tissues and organs, including those that do not normally contain neuroendocrine cells [<xref ref-type="bibr" rid="B1">1</xref>]. These tumors may occur in pure forms or in association with conventional adenocarcinomas or squamous cell carcinomas [<xref ref-type="bibr" rid="B2">2</xref>]. Neuroendocrine tumors of the kidney include carcinoids, atypical carcinoids, and small cell carcinomas [<xref ref-type="bibr" rid="B2">2</xref>]. Intrarenal pheochromocytoma, neuroblastoma, and primitive neuroectodermal tumors may also occur [<xref ref-type="bibr" rid="B3">3</xref>]. They may present clinically with gross hematuria or as a mass detected on imaging studies. NE lesions of the kidney are currently classified as well- or poorly-differentiated, both being extremely uncommon [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B4">4</xref>]. Well-differentiated neuroendocrine tumors of renal origin are usually carcinoids, and fewer than 56 cases have been reported in the literature [<xref ref-type="bibr" rid="B5">5</xref>]. There is an interesting, and as yet unexplained, association of renal carcinoids with horseshoe kidneys [<xref ref-type="bibr" rid="B5">5</xref>-<xref ref-type="bibr" rid="B7">7</xref>]. The behavior of renal carinoids is not well defined owing to the small number of reported cases, and therefore prognoses are difficult to predict. Patients with advanced disease have been reported to survive for long periods of time even in the presence of tumor spread [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B8">8</xref>]. Progression of hepatic metastases is the predominant cause of death in patients with gastrointestinal and other cancers. For this reason the treatment of these lesions has been the focus of multiple therapeutic approaches. We report a case of a carcinoid from renal origin with a synchronous single liver metastasis on radiological studies. We will discuss different aspects of this unusual tumor, with emphasis on the treatment of liver metastases.</p>
    </sec>
    <sec>
      <title>Case presentation</title>
      <p>We evaluated a 45 year-old patient who presented initially with abdominal pain. Abdominal and pelvic CT scan showed lesions in the right ovary, right kidney, and left hepatic lobe. The right kidney mass was 8.0 cm in diameter, with areas of calcification in the periphery of the tumor inferiorly (Figure <xref ref-type="fig" rid="F1">1</xref>). In addition, there was one liver lesion, 9.7 cm in greatest diameter, located in segments 2 and 3 with extension into segment 4 of the left lobe (Figure <xref ref-type="fig" rid="F2">2</xref>). The liver and kidney tumors showed similar densities on CT scan. The right ovarian mass was multiloculated, measuring 8.7 cm in diameter. The uterus and left ovary appeared normal. CT scan of the chest showed no lesions. Tumor markers CA-125, CEA and CA 19-9 were within normal limits, as were preoperative liver function tests and renal function. A percutaneous biopsy of the liver mass was performed, which the pathologist reported to be metastatic neuroendocrine tumor. The patient was subsequently taken to the operating room, where she explored through a long midline incision; extensive abdominal examination was performed and no peritoneal seeding was found. The right ovary was removed first and sent for frozen section. Pathology reported a borderline tumor of the ovary; a total abdominal hysterectomy with bilateral salpingo-oophorectomy was performed. This was followed by a radical right nephrectomy with lymphadenectomy and a formal left hepatectomy. Final pathology reported a right ovarian borderline serous tumor, well-differentiated neuroendocrine carcinoma of the kidney (carcinoid) with 2 positive retroperitoneal lymph nodes, and a single liver metastasis. Immunohistochemistry revealed that this lesion was positive for synaptophysin and CD56, but negative for chromogranin as well as CD10, CD7, and CD20. These features are consistent with a well-differentiated neuroendocrine tumor. An octreotide scan was performed 2 months after surgery, which suggested the possibility of positive retroperitoneal lymph nodes. The patient underwent a laparoscopic left retroperitoneal para-aortic lymph node dissection, and 2 out of 5 lymph nodes were positive for tumor, with histologic features similar to the original lesions. The patient is doing well one year after her initial surgery, with no evidence of tumor recurrence.</p>
      <fig position="float" id="F1">
        <label>Figure 1</label>
        <caption>
          <p>CT image showing the primary lesion in the right kidney.</p>
        </caption>
        <graphic xlink:href="1477-7819-6-41-1"/>
      </fig>
      <fig position="float" id="F2">
        <label>Figure 2</label>
        <caption>
          <p>CT image showing the metastatic lesion in segments 2, 3 and 4 of the left hepatic lobe.</p>
        </caption>
        <graphic xlink:href="1477-7819-6-41-2"/>
      </fig>
    </sec>
    <sec>
      <title>Discussion</title>
      <p>Carcinoid tumors are characteristically low grade malignant neoplasms with neuroendocrine differentiation that arise in various body sites, most commonly the lung and gastrointestinal tract, but less frequently the kidneys, breasts, ovaries, testes, prostate and other locations. The prognosis of carcinoid tumors of renal origin is unclear due to the rarity of these lesions. The pathogenesis of renal carcinoid tumors (RCT) is controversial. Several hypotheses support that RCT are derived from interspersed neuroendocrine cells associated with acquired and congenital abnormalities such as metaplasia of pyelocaliceal urothelium induced by chronic inflammation, misplaced or entrapped neural crest or pancreatic tissue in the kidney during embryogenesis, activation of gene sequences common to neuroendocrine programmed cells in multipotent stem cells, or concurrent congenital abnormalities [<xref ref-type="bibr" rid="B9">9</xref>-<xref ref-type="bibr" rid="B12">12</xref>].</p>
      <p>In 2006, an extensive review of the literature on primary RCT was published by Romero <italic>et al</italic>. [<xref ref-type="bibr" rid="B5">5</xref>]. In this report, the authors collected all previous reports by other centers for a total of 56 cases. Renal carcinoids were associated with another renal pathology in 26.8% of cases [<xref ref-type="bibr" rid="B5">5</xref>]. Only 7% of these patients presented with carcinoid syndrome at the time of diagnosis; interestingly, 4 other patients (7%) presented with symptoms related to other neuroendocrine syndromes. The median patient age was 49 years, with a range of 12 to 68 years. Calcifications were present on 26.5% of imaging studies. Median tumor size was 8.4 cm (range 1.5 to 30 cm) with 73.6% of patients presenting with tumors greater than 4 cm. Microscopically, 62.5% of lesions showed a mixed growth pattern with 65% demonstrating a predominant trabecular or ribbon-like growth pattern. Mitotic figures were absent or rare in 83.3% of reported cases. Immunohistochemistry demonstrated many different patterns; nevertheless, most lesions were positive for Grimelius, synaptophysin, neuron-specific enolase and chromogranin but negative for Fontana-Masson. Metastases were present in 50% of cases with para-aortic and hilar lymph nodes being the most common locations. Liver metastases occurred in 34% of cases. Metastases to the bone and spleen were also described but were much less common. Surgery was considered the treatment of choice for RCT, and long-term survival was achieved even in patients with lymph node metastases. Tumor size smaller than 4 cm at the time of diagnosis and lesions confined to the kidney were associated with a lesser incidence of metastases and better prognosis [<xref ref-type="bibr" rid="B5">5</xref>]. Mitotic rate was also implicated as a prognostic pathological factor.</p>
      <p>The octreotide scan is considered the most important investigation for surveillance after resection. Following chromogranin and 5-HIAA is also recommended, even in the absence of symptoms. Additional neuroendocrine markers can be tested if they were found to be positive prior to surgery. CT and/or MRI can be used as imaging studies for surveillance. New metastases have been reported as long as 7 years after resection, indicating that long term follow up is needed.</p>
      <p>The treatment of liver metastases from RCT is not well defined due to scarcity of cases. Most of the experience regarding the treatment of metastatic neuroendocrine disease in the liver comes from those tumors originating in the gastrointestinal tract, and in these cases, the mainstay of treatment is resection [<xref ref-type="bibr" rid="B13">13</xref>-<xref ref-type="bibr" rid="B15">15</xref>]. In our patient, an aggressive surgical approach including resection of the liver metastasis was chosen based on the biopsy results demonstrating a neuroendocrine tumor, the fact that the lesion was solitary, and that an anatomic resection could be performed to achieve negative margins. In the last few years some authors have suggested that even in the presence of extensive disease, liver resection for cytoreduction may be not only palliative, but also may increase survival [<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B17">17</xref>]. Nagorney <italic>et al. </italic>[<xref ref-type="bibr" rid="B16">16</xref>] have proposed that surgical resection is indicated if the primary lesion is resectable or has been resected, which makes 90% of liver metastases either resectable or ablatable. An impressive 4-year survival rate of 75% has been achieved with this approach. Interestingly, they showed no survival difference between patients undergoing complete versus incomplete resection. Other reports have showed that resection of neuroendocrine tumors may achieve 5-year survival rates in the range of 47 to 92% [<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B18">18</xref>,<xref ref-type="bibr" rid="B19">19</xref>], with resolution of symptoms in more that 90% and very low operative mortality.</p>
      <p>Tumor recurrence has been a major problem after surgical treatment. Resection, ablation, or both in combination can be used to treat tumor recurrence [<xref ref-type="bibr" rid="B16">16</xref>]. Extensive intrahepatic recurrence can be treated with either embolization or chemoembolization, since these are usually hypervascular lesions. Systemic chemotherapy may be used in the presence of extrahepatic spread of disease [<xref ref-type="bibr" rid="B20">20</xref>-<xref ref-type="bibr" rid="B22">22</xref>]. Patients with pancreatic neuroendocrine tumors have been more responsive to chemotherapy than carcinoids. Since carcinoid lesions are low-grade, well-differentiated tumors with a low proliferation index, they are less likely to be responsive to chemotherapy. Somatostatin analogues like octreotide and more recently lanreotide, which can be given monthly, have been utilized to treat patients with advanced disease. Response rate has been variable and may correlate to octreotide scan, but stabilization of disease has been seen in 36 to 70% of patients, with a mean duration of 12 months [<xref ref-type="bibr" rid="B23">23</xref>]. Interferon alfa has also been used in neuroendocrine tumors with low objective response rate, but stabilization of the disease has been observed in 40 to 60% of cases [<xref ref-type="bibr" rid="B16">16</xref>].</p>
    </sec>
    <sec>
      <title>Conclusion</title>
      <p>Early surgical intervention, together with careful surveillance and follow-up, can achieve successful long-term outcomes in patients with this rare malignancy.</p>
    </sec>
    <sec>
      <title>Competing interests</title>
      <p>The authors declare that they have no competing interests.</p>
    </sec>
    <sec>
      <title>Authors' contributions</title>
      <p>RG and RGR conceived of the study; RG conducted literature review and prepared the draft manuscript; RG, HJ, TDJ, PPM, and RGR performed critical editing of content and helped in preparation of the manuscript; RG and DR edited the final version. All authors read and approved of the final version of the manuscript</p>
    </sec>
  </body>
  <back>
    <ack>
      <sec>
        <title>Acknowledgements</title>
        <p>Written informed consent was obtained from the patient for publication of this case report.</p>
      </sec>
    </ack>
    <ref-list>
      <ref id="B1">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zuetenhorst</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Taal</surname>
              <given-names>BG</given-names>
            </name>
          </person-group>
          <article-title>Metastatic carcinoid tumors: a clinical review</article-title>
          <source>Oncologist</source>
          <year>2005</year>
          <volume>10</volume>
          <fpage>123</fpage>
          <lpage>131</lpage>
          <pub-id pub-id-type="pmid">15709214</pub-id>
          <pub-id pub-id-type="doi">10.1634/theoncologist.10-2-123</pub-id>
        </citation>
      </ref>
      <ref id="B2">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Osamura</surname>
              <given-names>RY</given-names>
            </name>
            <name>
              <surname>Chie</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Kajiwara</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>DeLellis</surname>
              <given-names>RA</given-names>
            </name>
          </person-group>
          <article-title>Neuroendocrine carcinomas of diverse sites</article-title>
          <source>Pathology Case Reviews</source>
          <year>2006</year>
          <volume>11</volume>
          <fpage>282</fpage>
          <lpage>291</lpage>
          <pub-id pub-id-type="doi">10.1097/01.pcr.0000251136.88078.43</pub-id>
        </citation>
      </ref>
      <ref id="B3">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Parham</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Roloson</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Feely</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Green</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Bridge</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Beckwith</surname>
              <given-names>JB</given-names>
            </name>
          </person-group>
          <article-title>Primary malignant neuroepithelial tumors of the kidney: a clinicopathologic analysis of 146 adult and pediatric cases from the National Wilms' Tumor Study Group Pathology Center</article-title>
          <source>Am J Surg Pathol</source>
          <year>2001</year>
          <volume>25</volume>
          <fpage>133</fpage>
          <lpage>146</lpage>
          <pub-id pub-id-type="pmid">11176062</pub-id>
          <pub-id pub-id-type="doi">10.1097/00000478-200102000-00001</pub-id>
        </citation>
      </ref>
      <ref id="B4">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kurl</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Rytkonen</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Farin</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Ala-Opas</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Soimakallio</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>A primary carcinoid tumor of the kidney: a case report and review of the literature</article-title>
          <source>Abdom Imaging</source>
          <year>1996</year>
          <volume>21</volume>
          <fpage>464</fpage>
          <lpage>467</lpage>
          <pub-id pub-id-type="pmid">8832873</pub-id>
          <pub-id pub-id-type="doi">10.1007/s002619900106</pub-id>
        </citation>
      </ref>
      <ref id="B5">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Romero</surname>
              <given-names>FR</given-names>
            </name>
            <name>
              <surname>Rais-Bahrami</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Permpongkosol</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Fine</surname>
              <given-names>SW</given-names>
            </name>
            <name>
              <surname>Kohanim</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Jarrett</surname>
              <given-names>TW</given-names>
            </name>
          </person-group>
          <article-title>Primary carcinoid tumors of the kidney</article-title>
          <source>J Urol</source>
          <year>2006</year>
          <volume>176</volume>
          <fpage>2359</fpage>
          <lpage>2366</lpage>
          <pub-id pub-id-type="pmid">17085102</pub-id>
          <pub-id pub-id-type="doi">10.1016/j.juro.2006.07.129</pub-id>
        </citation>
      </ref>
      <ref id="B6">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rodriguez-Covarrubias</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Gomez</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Valerio</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Lome-Maldonado</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Gabilondo</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Carcinoid tumor arising in a horseshoe kidney</article-title>
          <source>Int Urol Nephrol</source>
          <year>2006</year>
          <pub-id pub-id-type="pmid">16835722</pub-id>
        </citation>
      </ref>
      <ref id="B7">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Isobe</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Takashima</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Higashi</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Murakami</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Fujita</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Hanazawa</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Fujime</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Matsumoto</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Primary carcinoid tumor in a horseshoe kidney</article-title>
          <source>Int J Urol</source>
          <year>2000</year>
          <volume>7</volume>
          <fpage>184</fpage>
          <lpage>188</lpage>
          <pub-id pub-id-type="pmid">10830826</pub-id>
          <pub-id pub-id-type="doi">10.1046/j.1442-2042.2000.00160.x</pub-id>
        </citation>
      </ref>
      <ref id="B8">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McCaffrey</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Reuter</surname>
              <given-names>VV</given-names>
            </name>
            <name>
              <surname>Herr</surname>
              <given-names>HW</given-names>
            </name>
            <name>
              <surname>Macapinlac</surname>
              <given-names>HA</given-names>
            </name>
            <name>
              <surname>Russo</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Motzer</surname>
              <given-names>RJ</given-names>
            </name>
          </person-group>
          <article-title>Carcinoid tumor of the kidney. The use of somatostatin receptor scintigraphy in diagnosis and management</article-title>
          <source>Urol Oncol</source>
          <year>2000</year>
          <volume>5</volume>
          <fpage>108</fpage>
          <lpage>111</lpage>
          <pub-id pub-id-type="pmid">10765017</pub-id>
          <pub-id pub-id-type="doi">10.1016/S1078-1439(99)00050-2</pub-id>
        </citation>
      </ref>
      <ref id="B9">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Begin</surname>
              <given-names>LR</given-names>
            </name>
            <name>
              <surname>Guy</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Jacobson</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Aprikian</surname>
              <given-names>AG</given-names>
            </name>
          </person-group>
          <article-title>Renal carcinoid and horseshoe kidney: a frequent association of two rare entities &#x2013; a case report and review of the literature</article-title>
          <source>J Surg Oncol</source>
          <year>1998</year>
          <volume>68</volume>
          <fpage>113</fpage>
          <lpage>119</lpage>
          <pub-id pub-id-type="pmid">9624041</pub-id>
          <pub-id pub-id-type="doi">10.1002/(SICI)1096-9098(199806)68:2&lt;113::AID-JSO8&gt;3.0.CO;2-9</pub-id>
        </citation>
      </ref>
      <ref id="B10">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yoo</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Jung Lee</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Jin Kang</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kee Kim</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Primary carcinoid tumor arising in a mature teratoma of the kidney: a case report and review of the literature</article-title>
          <source>Arch Pathol Lab Med</source>
          <year>2002</year>
          <volume>126</volume>
          <fpage>979</fpage>
          <lpage>981</lpage>
          <pub-id pub-id-type="pmid">12171501</pub-id>
        </citation>
      </ref>
      <ref id="B11">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schlussel</surname>
              <given-names>RN</given-names>
            </name>
            <name>
              <surname>Kirschenbaum</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Levine</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Unger</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Primary renal carcinoid tumor</article-title>
          <source>Urology</source>
          <year>1993</year>
          <volume>41</volume>
          <fpage>295</fpage>
          <lpage>297</lpage>
          <pub-id pub-id-type="pmid">8442319</pub-id>
          <pub-id pub-id-type="doi">10.1016/0090-4295(93)90581-T</pub-id>
        </citation>
      </ref>
      <ref id="B12">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Muthuphei</surname>
              <given-names>MN</given-names>
            </name>
          </person-group>
          <article-title>Primary renal carcinoid: report of a case</article-title>
          <source>Cent Afr J Med</source>
          <year>1999</year>
          <volume>45</volume>
          <fpage>327</fpage>
          <lpage>329</lpage>
          <pub-id pub-id-type="pmid">10941411</pub-id>
        </citation>
      </ref>
      <ref id="B13">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Hardacre</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Uzar</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Cameron</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Choti</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
          <article-title>Isolated liver metastases from neuroendocrine tumors: does resection prolong survival?</article-title>
          <source>J Am Coll Surg</source>
          <year>1998</year>
          <volume>187</volume>
          <fpage>88</fpage>
          <lpage>92</lpage>
          <comment>discussion 92&#x2013;83.</comment>
          <pub-id pub-id-type="pmid">9660030</pub-id>
          <pub-id pub-id-type="doi">10.1016/S1072-7515(98)00099-4</pub-id>
        </citation>
      </ref>
      <ref id="B14">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Grazi</surname>
              <given-names>GL</given-names>
            </name>
            <name>
              <surname>Cescon</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Pierangeli</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Ercolani</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Gardini</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Cavallari</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Mazziotti</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Highly aggressive policy of hepatic resections for neuroendocrine liver metastases</article-title>
          <source>Hepatogastroenterology</source>
          <year>2000</year>
          <volume>47</volume>
          <fpage>481</fpage>
          <lpage>486</lpage>
          <pub-id pub-id-type="pmid">10791218</pub-id>
        </citation>
      </ref>
      <ref id="B15">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sarmiento</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Heywood</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Rubin</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ilstrup</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Nagorney</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Que</surname>
              <given-names>FG</given-names>
            </name>
          </person-group>
          <article-title>Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival</article-title>
          <source>J Am Coll Surg</source>
          <year>2003</year>
          <volume>197</volume>
          <fpage>29</fpage>
          <lpage>37</lpage>
          <pub-id pub-id-type="pmid">12831921</pub-id>
          <pub-id pub-id-type="doi">10.1016/S1072-7515(03)00230-8</pub-id>
        </citation>
      </ref>
      <ref id="B16">
        <citation citation-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>DM Nagorney</surname>
              <given-names>TDA</given-names>
            </name>
            <name>
              <surname>Que</surname>
              <given-names>FG</given-names>
            </name>
          </person-group>
          <article-title>Hepatic metastases from primary neuroendocrine tumors</article-title>
          <source>Surgery of the Liver Biliary Tract and Pancreas</source>
          <year>2007</year>
          <publisher-name>Blumgart LH: Saunders</publisher-name>
          <fpage>1195</fpage>
          <lpage>1217</lpage>
        </citation>
      </ref>
      <ref id="B17">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Musunuru</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Rajpal</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Stephani</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>McDermott</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Holen</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Rikkers</surname>
              <given-names>LF</given-names>
            </name>
            <name>
              <surname>Weber</surname>
              <given-names>SM</given-names>
            </name>
          </person-group>
          <article-title>Metastatic neuroendocrine hepatic tumors: resection improves survival</article-title>
          <source>Arch Surg</source>
          <year>2006</year>
          <volume>141</volume>
          <fpage>1000</fpage>
          <lpage>1004</lpage>
          <comment>discussion 1005.</comment>
          <pub-id pub-id-type="pmid">17043278</pub-id>
          <pub-id pub-id-type="doi">10.1001/archsurg.141.10.1000</pub-id>
        </citation>
      </ref>
      <ref id="B18">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nave</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Mossinger</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Feist</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Lang</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Raab</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Surgery as primary treatment in patients with liver metastases from carcinoid tumors: a retrospective, unicentric study over 13 years</article-title>
          <source>Surgery</source>
          <year>2001</year>
          <volume>129</volume>
          <fpage>170</fpage>
          <lpage>175</lpage>
          <pub-id pub-id-type="pmid">11174710</pub-id>
          <pub-id pub-id-type="doi">10.1067/msy.2001.110426</pub-id>
        </citation>
      </ref>
      <ref id="B19">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Norton</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Warren</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Kelly</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Zuraek</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Jensen</surname>
              <given-names>RT</given-names>
            </name>
          </person-group>
          <article-title>Aggressive surgery for metastatic liver neuroendocrine tumors</article-title>
          <source>Surgery</source>
          <year>2003</year>
          <volume>134</volume>
          <fpage>1057</fpage>
          <lpage>1063</lpage>
          <comment>discussion 1063&#x2013;1055.</comment>
          <pub-id pub-id-type="pmid">14668741</pub-id>
          <pub-id pub-id-type="doi">10.1016/j.surg.2003.07.025</pub-id>
        </citation>
      </ref>
      <ref id="B20">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kaltsas</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Mukherjee</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Plowman</surname>
              <given-names>PN</given-names>
            </name>
            <name>
              <surname>Grossman</surname>
              <given-names>AB</given-names>
            </name>
          </person-group>
          <article-title>The role of chemotherapy in the nonsurgical management of malignant neuroendocrine tumours</article-title>
          <source>Clin Endocrinol (Oxf)</source>
          <year>2001</year>
          <volume>55</volume>
          <fpage>575</fpage>
          <lpage>587</lpage>
          <pub-id pub-id-type="pmid">11894967</pub-id>
          <pub-id pub-id-type="doi">10.1046/j.1365-2265.2001.01396.x</pub-id>
        </citation>
      </ref>
      <ref id="B21">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oberg</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Diagnosis and treatment of carcinoid tumors</article-title>
          <source>Expert Rev Anticancer Ther</source>
          <year>2003</year>
          <volume>3</volume>
          <fpage>863</fpage>
          <lpage>877</lpage>
          <pub-id pub-id-type="pmid">14686708</pub-id>
          <pub-id pub-id-type="doi">10.1586/14737140.3.6.863</pub-id>
        </citation>
      </ref>
      <ref id="B22">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rivera</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Ajani</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
          <article-title>Doxorubicin, streptozocin, and 5-fluorouracil chemotherapy for patients with metastatic islet-cell carcinoma</article-title>
          <source>Am J Clin Oncol</source>
          <year>1998</year>
          <volume>21</volume>
          <fpage>36</fpage>
          <lpage>38</lpage>
          <pub-id pub-id-type="pmid">9499254</pub-id>
          <pub-id pub-id-type="doi">10.1097/00000421-199802000-00008</pub-id>
        </citation>
      </ref>
      <ref id="B23">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oberg</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Astrup</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Eriksson</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Falkmer</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Falkmer</surname>
              <given-names>UG</given-names>
            </name>
            <name>
              <surname>Gustafsen</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Haglund</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Knigge</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Vatn</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Valimaki</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part II-specific NE tumour types</article-title>
          <source>Acta Oncol</source>
          <year>2004</year>
          <volume>43</volume>
          <fpage>626</fpage>
          <lpage>636</lpage>
          <pub-id pub-id-type="pmid">15545183</pub-id>
          <pub-id pub-id-type="doi">10.1080/02841860410018584</pub-id>
        </citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
